person · Reporting owner
Redman Michael Thomas
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Genprex, Inc.GNPX · Entity 8441 | EVP & Chief Operating Officer | March 19, 2021 | March 23, 2021 |
| Oncolix, Inc.AEPP · Entity 165137 | Director · President | August 03, 2017 | September 14, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Genprex, Inc.
Report date March 19, 2021 · Filed March 23, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.08 · Expires 2031-03-19 | Direct | 200,000 |
Reported balance
After 2021-03-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-03-19 · Grant · Acquired 200,000 · Balance 200,000 F1: One third (1/3) of the Shares subject to the Option shall vest on each annual anniversary of March 19, 2021 so that one hundred percent (100%) of the shares subject to the Option are vested on the third anniversary of March 19, 2021, provided that the optionee continues to serve as a Service Provider (as defined in Genprex, Inc. 2018 Equity Incentive Plan) through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: One third (1/3) of the Shares subject to the Option shall vest on each annual anniversary of March 19, 2021 so that one hundred percent (100%) of the shares subject to the Option are vested on the third anniversary of March 19, 2021, provided that the optionee continues to serve as a Service Provider (as defined in Genprex, Inc. 2018 Equity Incentive Plan) through the applicable vesting date.
Oncolix, Inc.
Report date August 03, 2017 · Filed September 14, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,828,000 |
Reported balance
After 2017-08-03 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2017-08-03 · Grant · Acquired 4,400,000 · Balance 2,828,000 F1: On August 3, 2017, a wholly-owned subsidiary of AEPP, AEPP Merger Sub, Inc., merged with and into Oncolix, Inc. Oncolix was the survivor of the merger (Merger) and Oncolix became a wholly-owned subsidiary of AEPP. In connection with the Merger, the Oncolix securities owned were converted into the right to receive securities of AEPP. F3: Includes (i) 14,000 shares of AEPP common stock issuable upon conversion of AEPP Series A Preferred stock; (ii) 14,000 shares of AEPP Series A Preferred Stock issuable upon exercise of warrants to acquire AEPP Series A Preferred Stock; (iii) 14,000 shares of shares of AEPP common stock issuable upon the conversion of AEPP Series A Preferred Stock that may be acquired pursuant to (ii) herein; and (iv) 2,800,000 shares of AEPP Common Stock that may be acquired pursuant to options. |
| Series A Preferred StockSEC Table I · non-derivative | Direct | 28,000 |
Reported balance
After 2017-08-03 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2017-08-03 · Grant · Acquired 14,000 · Balance 28,000 F1: On August 3, 2017, a wholly-owned subsidiary of AEPP, AEPP Merger Sub, Inc., merged with and into Oncolix, Inc. Oncolix was the survivor of the merger (Merger) and Oncolix became a wholly-owned subsidiary of AEPP. In connection with the Merger, the Oncolix securities owned were converted into the right to receive securities of AEPP. F3: Includes (i) 14,000 shares of AEPP common stock issuable upon conversion of AEPP Series A Preferred stock; (ii) 14,000 shares of AEPP Series A Preferred Stock issuable upon exercise of warrants to acquire AEPP Series A Preferred Stock; (iii) 14,000 shares of shares of AEPP common stock issuable upon the conversion of AEPP Series A Preferred Stock that may be acquired pursuant to (ii) herein; and (iv) 2,800,000 shares of AEPP Common Stock that may be acquired pursuant to options. |
| Common StockSEC Table I · non-derivative | Indirectsee footnote | 2,828,000 |
Reported balance
After 2017-08-03 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2017-08-03 · Disposition to issuer · Acquired 61,465,130 · Balance 2,828,000 F2: As reflected on his Form 3 filed on April 11, 2017, Mr. Redman may be deemed a beneficial owner of such 61,465,130 shares owned by Oncolix, Inc., as a result of Mr. Redman being an executive officer of Oncolix, Inc., however, Mr. Redman disclaimed any such beneficial ownership in the 61,465,130 shares owned by Oncolix, Inc. The 61,465,130 shares of common stock owned by Oncolix, Inc. were disposed to, and cancelled by, AEPP in connection with the Merger. While Mr. Reman disclaimed any such beneficial ownership, had he owned any such beneficial interest, Mr. Redman disposed of such beneficial ownership to AEPP in connection with such cancellation as provided for in the Merger. F3: Includes (i) 14,000 shares of AEPP common stock issuable upon conversion of AEPP Series A Preferred stock; (ii) 14,000 shares of AEPP Series A Preferred Stock issuable upon exercise of warrants to acquire AEPP Series A Preferred Stock; (iii) 14,000 shares of shares of AEPP common stock issuable upon the conversion of AEPP Series A Preferred Stock that may be acquired pursuant to (ii) herein; and (iv) 2,800,000 shares of AEPP Common Stock that may be acquired pursuant to options. |
| Series A Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.08 · Expires 2050-01-01 | Direct | 28,000 |
Reported balance
After 2017-08-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-08-03 · Grant · Acquired 14,000 · Balance 28,000 F1: On August 3, 2017, a wholly-owned subsidiary of AEPP, AEPP Merger Sub, Inc., merged with and into Oncolix, Inc. Oncolix was the survivor of the merger (Merger) and Oncolix became a wholly-owned subsidiary of AEPP. In connection with the Merger, the Oncolix securities owned were converted into the right to receive securities of AEPP. F4: Each share of Series A Preferred Stock is convertible into one share of Common Stock, subject to adjustment. There is no expiration date for conversion. F3: Includes (i) 14,000 shares of AEPP common stock issuable upon conversion of AEPP Series A Preferred stock; (ii) 14,000 shares of AEPP Series A Preferred Stock issuable upon exercise of warrants to acquire AEPP Series A Preferred Stock; (iii) 14,000 shares of shares of AEPP common stock issuable upon the conversion of AEPP Series A Preferred Stock that may be acquired pursuant to (ii) herein; and (iv) 2,800,000 shares of AEPP Common Stock that may be acquired pursuant to options. |
| Warrant to acquire Series A Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.08 · Expires 2020-01-16 | Direct | 28,000 |
Reported balance
After 2017-08-03 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2017-08-03 · Grant · Acquired 14,000 · Balance 28,000 F1: On August 3, 2017, a wholly-owned subsidiary of AEPP, AEPP Merger Sub, Inc., merged with and into Oncolix, Inc. Oncolix was the survivor of the merger (Merger) and Oncolix became a wholly-owned subsidiary of AEPP. In connection with the Merger, the Oncolix securities owned were converted into the right to receive securities of AEPP. |
| Option to acquire Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.01 · Expires 2021-04-25 | Direct | 4,800,000 |
Reported balance
After 2017-08-03 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2017-08-03 · Grant · Acquired 2,000,000 · Balance 4,800,000 F1: On August 3, 2017, a wholly-owned subsidiary of AEPP, AEPP Merger Sub, Inc., merged with and into Oncolix, Inc. Oncolix was the survivor of the merger (Merger) and Oncolix became a wholly-owned subsidiary of AEPP. In connection with the Merger, the Oncolix securities owned were converted into the right to receive securities of AEPP. |
| Option to acquire Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.02 · Expires 2021-11-28 | Direct | 4,800,000 |
Reported balance
After 2017-08-03 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2017-08-03 · Grant · Acquired 2,000,000 · Balance 4,800,000 F1: On August 3, 2017, a wholly-owned subsidiary of AEPP, AEPP Merger Sub, Inc., merged with and into Oncolix, Inc. Oncolix was the survivor of the merger (Merger) and Oncolix became a wholly-owned subsidiary of AEPP. In connection with the Merger, the Oncolix securities owned were converted into the right to receive securities of AEPP. |
| Option to acquire Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.01 · Expires 2021-11-28 | Direct | 4,800,000 |
Reported balance
After 2017-08-03 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2017-08-03 · Grant · Acquired 800,000 · Balance 4,800,000 F1: On August 3, 2017, a wholly-owned subsidiary of AEPP, AEPP Merger Sub, Inc., merged with and into Oncolix, Inc. Oncolix was the survivor of the merger (Merger) and Oncolix became a wholly-owned subsidiary of AEPP. In connection with the Merger, the Oncolix securities owned were converted into the right to receive securities of AEPP. |
Filing footnotes · ownership attribution and instrument terms
F1: On August 3, 2017, a wholly-owned subsidiary of AEPP, AEPP Merger Sub, Inc., merged with and into Oncolix, Inc. Oncolix was the survivor of the merger (Merger) and Oncolix became a wholly-owned subsidiary of AEPP. In connection with the Merger, the Oncolix securities owned were converted into the right to receive securities of AEPP.
F2: As reflected on his Form 3 filed on April 11, 2017, Mr. Redman may be deemed a beneficial owner of such 61,465,130 shares owned by Oncolix, Inc., as a result of Mr. Redman being an executive officer of Oncolix, Inc., however, Mr. Redman disclaimed any such beneficial ownership in the 61,465,130 shares owned by Oncolix, Inc. The 61,465,130 shares of common stock owned by Oncolix, Inc. were disposed to, and cancelled by, AEPP in connection with the Merger. While Mr. Reman disclaimed any such beneficial ownership, had he owned any such beneficial interest, Mr. Redman disposed of such beneficial ownership to AEPP in connection with such cancellation as provided for in the Merger.
F3: Includes (i) 14,000 shares of AEPP common stock issuable upon conversion of AEPP Series A Preferred stock; (ii) 14,000 shares of AEPP Series A Preferred Stock issuable upon exercise of warrants to acquire AEPP Series A Preferred Stock; (iii) 14,000 shares of shares of AEPP common stock issuable upon the conversion of AEPP Series A Preferred Stock that may be acquired pursuant to (ii) herein; and (iv) 2,800,000 shares of AEPP Common Stock that may be acquired pursuant to options.
F4: Each share of Series A Preferred Stock is convertible into one share of Common Stock, subject to adjustment. There is no expiration date for conversion.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 19, 2021 Filed Mar 23, 2021 20:46 UTC | Genprex, Inc. GNPX · Entity 8441 | GrantStock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $5.08 | $0.00 |
DisclosureSEC source: 0001437749-21-006912 · rdgdoc.xml · derivative · entry 1 Redman Michael Thomas · CIK 0001703052 · EVP & Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2031-03-19 F1 · derivative.exercise_date: One third (1/3) of the Shares subject to the Option shall vest on each annual anniversary of March 19, 2021 so that one hundred percent (100%) of the shares subject to the Option are vested on the third anniversary of March 19, 2021, provided that the optionee continues to serve as a Service Provider (as defined in Genprex, Inc. 2018 Equity Incentive Plan) through the applicable vesting date. Read SEC document |
| August 03, 2017 Filed Sep 14, 2017 12:58 UTC | Oncolix, Inc. AEPP · Entity 165137 | GrantOption to acquire Common Stock · Derivative | 800,000 | Not disclosed Strike: $0.01 | Not disclosed |
DisclosureSEC source: 0001703052-17-000002 · primary_doc.xml · derivative · entry 8 Redman Michael Thomas · CIK 0001703052 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,800,000 Underlying: Common Stock · 800,000 shares Expires 2021-11-28 F1 · price: On August 3, 2017, a wholly-owned subsidiary of AEPP, AEPP Merger Sub, Inc., merged with and into Oncolix, Inc. Oncolix was the survivor of the merger (Merger) and Oncolix became a wholly-owned subsidiary of AEPP. In connection with the Merger, the Oncolix securities owned were converted into the right to receive securities of AEPP. Read SEC document |
| August 03, 2017 Filed Sep 14, 2017 12:58 UTC | Oncolix, Inc. AEPP · Entity 165137 | GrantOption to acquire Common Stock · Derivative | 2,000,000 | Not disclosed Strike: $0.02 | Not disclosed |
DisclosureSEC source: 0001703052-17-000002 · primary_doc.xml · derivative · entry 7 Redman Michael Thomas · CIK 0001703052 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,800,000 Underlying: Common Stock · 2,000,000 shares Expires 2021-11-28 F1 · shares: On August 3, 2017, a wholly-owned subsidiary of AEPP, AEPP Merger Sub, Inc., merged with and into Oncolix, Inc. Oncolix was the survivor of the merger (Merger) and Oncolix became a wholly-owned subsidiary of AEPP. In connection with the Merger, the Oncolix securities owned were converted into the right to receive securities of AEPP. F1 · price: On August 3, 2017, a wholly-owned subsidiary of AEPP, AEPP Merger Sub, Inc., merged with and into Oncolix, Inc. Oncolix was the survivor of the merger (Merger) and Oncolix became a wholly-owned subsidiary of AEPP. In connection with the Merger, the Oncolix securities owned were converted into the right to receive securities of AEPP. Read SEC document |
| August 03, 2017 Filed Sep 14, 2017 12:58 UTC | Oncolix, Inc. AEPP · Entity 165137 | GrantOption to acquire Common Stock · Derivative | 2,000,000 | Not disclosed Strike: $0.01 | Not disclosed |
DisclosureSEC source: 0001703052-17-000002 · primary_doc.xml · derivative · entry 6 Redman Michael Thomas · CIK 0001703052 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,800,000 Underlying: Common Stock · 2,000,000 shares Expires 2021-04-25 F1 · shares: On August 3, 2017, a wholly-owned subsidiary of AEPP, AEPP Merger Sub, Inc., merged with and into Oncolix, Inc. Oncolix was the survivor of the merger (Merger) and Oncolix became a wholly-owned subsidiary of AEPP. In connection with the Merger, the Oncolix securities owned were converted into the right to receive securities of AEPP. F1 · price: On August 3, 2017, a wholly-owned subsidiary of AEPP, AEPP Merger Sub, Inc., merged with and into Oncolix, Inc. Oncolix was the survivor of the merger (Merger) and Oncolix became a wholly-owned subsidiary of AEPP. In connection with the Merger, the Oncolix securities owned were converted into the right to receive securities of AEPP. F1 · balance_after: On August 3, 2017, a wholly-owned subsidiary of AEPP, AEPP Merger Sub, Inc., merged with and into Oncolix, Inc. Oncolix was the survivor of the merger (Merger) and Oncolix became a wholly-owned subsidiary of AEPP. In connection with the Merger, the Oncolix securities owned were converted into the right to receive securities of AEPP. Read SEC document |
| August 03, 2017 Filed Sep 14, 2017 12:58 UTC | Oncolix, Inc. AEPP · Entity 165137 | GrantWarrant to acquire Series A Preferred Stock · Derivative | 14,000 | Not disclosed Strike: $0.08 | Not disclosed |
DisclosureSEC source: 0001703052-17-000002 · primary_doc.xml · derivative · entry 5 Redman Michael Thomas · CIK 0001703052 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,000 Underlying: Series A Preferred Stock · 14,000 shares Expires 2020-01-16 F1 · shares: On August 3, 2017, a wholly-owned subsidiary of AEPP, AEPP Merger Sub, Inc., merged with and into Oncolix, Inc. Oncolix was the survivor of the merger (Merger) and Oncolix became a wholly-owned subsidiary of AEPP. In connection with the Merger, the Oncolix securities owned were converted into the right to receive securities of AEPP. F1 · price: On August 3, 2017, a wholly-owned subsidiary of AEPP, AEPP Merger Sub, Inc., merged with and into Oncolix, Inc. Oncolix was the survivor of the merger (Merger) and Oncolix became a wholly-owned subsidiary of AEPP. In connection with the Merger, the Oncolix securities owned were converted into the right to receive securities of AEPP. Read SEC document |
| August 03, 2017 Filed Sep 14, 2017 12:58 UTC | Oncolix, Inc. AEPP · Entity 165137 | GrantSeries A Preferred Stock · Derivative | 14,000 | Not disclosed Strike: $0.08 | Not disclosed |
DisclosureSEC source: 0001703052-17-000002 · primary_doc.xml · derivative · entry 4 Redman Michael Thomas · CIK 0001703052 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,000 Underlying: Common Stock · 14,000 shares Expires 2050-01-01 F1 · derivative.exercise_price: On August 3, 2017, a wholly-owned subsidiary of AEPP, AEPP Merger Sub, Inc., merged with and into Oncolix, Inc. Oncolix was the survivor of the merger (Merger) and Oncolix became a wholly-owned subsidiary of AEPP. In connection with the Merger, the Oncolix securities owned were converted into the right to receive securities of AEPP. F4 · derivative.exercise_price: Each share of Series A Preferred Stock is convertible into one share of Common Stock, subject to adjustment. There is no expiration date for conversion. F1 · shares: On August 3, 2017, a wholly-owned subsidiary of AEPP, AEPP Merger Sub, Inc., merged with and into Oncolix, Inc. Oncolix was the survivor of the merger (Merger) and Oncolix became a wholly-owned subsidiary of AEPP. In connection with the Merger, the Oncolix securities owned were converted into the right to receive securities of AEPP. F4 · shares: Each share of Series A Preferred Stock is convertible into one share of Common Stock, subject to adjustment. There is no expiration date for conversion. F1 · price: On August 3, 2017, a wholly-owned subsidiary of AEPP, AEPP Merger Sub, Inc., merged with and into Oncolix, Inc. Oncolix was the survivor of the merger (Merger) and Oncolix became a wholly-owned subsidiary of AEPP. In connection with the Merger, the Oncolix securities owned were converted into the right to receive securities of AEPP. F4 · derivative.expiration_date: Each share of Series A Preferred Stock is convertible into one share of Common Stock, subject to adjustment. There is no expiration date for conversion. F3 · balance_after: Includes (i) 14,000 shares of AEPP common stock issuable upon conversion of AEPP Series A Preferred stock; (ii) 14,000 shares of AEPP Series A Preferred Stock issuable upon exercise of warrants to acquire AEPP Series A Preferred Stock; (iii) 14,000 shares of shares of AEPP common stock issuable upon the conversion of AEPP Series A Preferred Stock that may be acquired pursuant to (ii) herein; and (iv) 2,800,000 shares of AEPP Common Stock that may be acquired pursuant to options. Read SEC document |
| August 03, 2017 Filed Sep 14, 2017 12:58 UTC | Oncolix, Inc. AEPP · Entity 165137 | Disposition to issuerCommon Stock | 61,465,130 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001703052-17-000002 · primary_doc.xml · nonDerivative · entry 3 Redman Michael Thomas · CIK 0001703052 · Director · President 10b5-1 filing: Not disclosed Ownership: Indirect · see footnote Disclosed balance after: 2,828,000 F2 · shares: As reflected on his Form 3 filed on April 11, 2017, Mr. Redman may be deemed a beneficial owner of such 61,465,130 shares owned by Oncolix, Inc., as a result of Mr. Redman being an executive officer of Oncolix, Inc., however, Mr. Redman disclaimed any such beneficial ownership in the 61,465,130 shares owned by Oncolix, Inc. The 61,465,130 shares of common stock owned by Oncolix, Inc. were disposed to, and cancelled by, AEPP in connection with the Merger. While Mr. Reman disclaimed any such beneficial ownership, had he owned any such beneficial interest, Mr. Redman disposed of such beneficial ownership to AEPP in connection with such cancellation as provided for in the Merger. F2 · price: As reflected on his Form 3 filed on April 11, 2017, Mr. Redman may be deemed a beneficial owner of such 61,465,130 shares owned by Oncolix, Inc., as a result of Mr. Redman being an executive officer of Oncolix, Inc., however, Mr. Redman disclaimed any such beneficial ownership in the 61,465,130 shares owned by Oncolix, Inc. The 61,465,130 shares of common stock owned by Oncolix, Inc. were disposed to, and cancelled by, AEPP in connection with the Merger. While Mr. Reman disclaimed any such beneficial ownership, had he owned any such beneficial interest, Mr. Redman disposed of such beneficial ownership to AEPP in connection with such cancellation as provided for in the Merger. F3 · balance_after: Includes (i) 14,000 shares of AEPP common stock issuable upon conversion of AEPP Series A Preferred stock; (ii) 14,000 shares of AEPP Series A Preferred Stock issuable upon exercise of warrants to acquire AEPP Series A Preferred Stock; (iii) 14,000 shares of shares of AEPP common stock issuable upon the conversion of AEPP Series A Preferred Stock that may be acquired pursuant to (ii) herein; and (iv) 2,800,000 shares of AEPP Common Stock that may be acquired pursuant to options. F2 · ownership.direct: As reflected on his Form 3 filed on April 11, 2017, Mr. Redman may be deemed a beneficial owner of such 61,465,130 shares owned by Oncolix, Inc., as a result of Mr. Redman being an executive officer of Oncolix, Inc., however, Mr. Redman disclaimed any such beneficial ownership in the 61,465,130 shares owned by Oncolix, Inc. The 61,465,130 shares of common stock owned by Oncolix, Inc. were disposed to, and cancelled by, AEPP in connection with the Merger. While Mr. Reman disclaimed any such beneficial ownership, had he owned any such beneficial interest, Mr. Redman disposed of such beneficial ownership to AEPP in connection with such cancellation as provided for in the Merger. F3 · ownership.direct: Includes (i) 14,000 shares of AEPP common stock issuable upon conversion of AEPP Series A Preferred stock; (ii) 14,000 shares of AEPP Series A Preferred Stock issuable upon exercise of warrants to acquire AEPP Series A Preferred Stock; (iii) 14,000 shares of shares of AEPP common stock issuable upon the conversion of AEPP Series A Preferred Stock that may be acquired pursuant to (ii) herein; and (iv) 2,800,000 shares of AEPP Common Stock that may be acquired pursuant to options. F2 · ownership.nature: As reflected on his Form 3 filed on April 11, 2017, Mr. Redman may be deemed a beneficial owner of such 61,465,130 shares owned by Oncolix, Inc., as a result of Mr. Redman being an executive officer of Oncolix, Inc., however, Mr. Redman disclaimed any such beneficial ownership in the 61,465,130 shares owned by Oncolix, Inc. The 61,465,130 shares of common stock owned by Oncolix, Inc. were disposed to, and cancelled by, AEPP in connection with the Merger. While Mr. Reman disclaimed any such beneficial ownership, had he owned any such beneficial interest, Mr. Redman disposed of such beneficial ownership to AEPP in connection with such cancellation as provided for in the Merger. Read SEC document |
| August 03, 2017 Filed Sep 14, 2017 12:58 UTC | Oncolix, Inc. AEPP · Entity 165137 | GrantSeries A Preferred Stock | 14,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001703052-17-000002 · primary_doc.xml · nonDerivative · entry 2 Redman Michael Thomas · CIK 0001703052 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,000 F1 · shares: On August 3, 2017, a wholly-owned subsidiary of AEPP, AEPP Merger Sub, Inc., merged with and into Oncolix, Inc. Oncolix was the survivor of the merger (Merger) and Oncolix became a wholly-owned subsidiary of AEPP. In connection with the Merger, the Oncolix securities owned were converted into the right to receive securities of AEPP. F1 · price: On August 3, 2017, a wholly-owned subsidiary of AEPP, AEPP Merger Sub, Inc., merged with and into Oncolix, Inc. Oncolix was the survivor of the merger (Merger) and Oncolix became a wholly-owned subsidiary of AEPP. In connection with the Merger, the Oncolix securities owned were converted into the right to receive securities of AEPP. F3 · balance_after: Includes (i) 14,000 shares of AEPP common stock issuable upon conversion of AEPP Series A Preferred stock; (ii) 14,000 shares of AEPP Series A Preferred Stock issuable upon exercise of warrants to acquire AEPP Series A Preferred Stock; (iii) 14,000 shares of shares of AEPP common stock issuable upon the conversion of AEPP Series A Preferred Stock that may be acquired pursuant to (ii) herein; and (iv) 2,800,000 shares of AEPP Common Stock that may be acquired pursuant to options. Read SEC document |
| August 03, 2017 Filed Sep 14, 2017 12:58 UTC | Oncolix, Inc. AEPP · Entity 165137 | GrantCommon Stock | 4,400,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001703052-17-000002 · primary_doc.xml · nonDerivative · entry 1 Redman Michael Thomas · CIK 0001703052 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,828,000 F1 · price: On August 3, 2017, a wholly-owned subsidiary of AEPP, AEPP Merger Sub, Inc., merged with and into Oncolix, Inc. Oncolix was the survivor of the merger (Merger) and Oncolix became a wholly-owned subsidiary of AEPP. In connection with the Merger, the Oncolix securities owned were converted into the right to receive securities of AEPP. F3 · balance_after: Includes (i) 14,000 shares of AEPP common stock issuable upon conversion of AEPP Series A Preferred stock; (ii) 14,000 shares of AEPP Series A Preferred Stock issuable upon exercise of warrants to acquire AEPP Series A Preferred Stock; (iii) 14,000 shares of shares of AEPP common stock issuable upon the conversion of AEPP Series A Preferred Stock that may be acquired pursuant to (ii) herein; and (iv) 2,800,000 shares of AEPP Common Stock that may be acquired pursuant to options. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.